The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail info@hpra.ie


Seretide 250 Diskus 50 microgram/250 microgram/dose inhalation powder, pre-dispensed



Merit Pharmaceuticals LimitedPPA23080/028/001

Main Information

Trade NameSeretide 250 Diskus 50 microgram/250 microgram/dose inhalation powder, pre-dispensed
Active SubstancesSalmeterol
Fluticasone propionate
Dosage FormInhalation powder, pre-dispensed
Licence HolderMerit Pharmaceuticals Limited
Licence NumberPPA23080/028/001

Group Information

ATC CodeR03AK06 salmeterol and fluticasone

Status

License statusAuthorised
Licence Issued02/06/2023
Legal statusProduct subject to prescription which may be renewed (B)
Supply StatusSupply through pharmacies only
Advertising StatusAdvertising to healthcare professionals only
Conditions of Licence
Marketing StatusUnknown

Documents

Summary of Product CharacteristicsPDF Version
Package LeafletPDF Version
Public Assessment ReportNo document available
« Back